Nursing and Health Professions
Patient with Type 2 Diabetes
85%
Cardiologist
71%
Non Insulin Dependent Diabetes Mellitus
57%
Sodium Glucose Cotransporter 2 Inhibitor
28%
Patient
28%
Inpatient
28%
Death
28%
Cardiovascular Risk
14%
Heart Failure
14%
Glucagon Like Peptide 1 Receptor Agonist
14%
Publication
14%
Glucagon Like Peptide
14%
Empagliflozin
14%
Cardiovascular Agent
14%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
14%
Liraglutide
14%
Semaglutide
14%
Renal Protection
14%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
57%
Cardiovascular System
28%
Patient with Diabetes
28%
Sodium Glucose Cotransporter 2 Inhibitor
28%
Therapeutic Procedure
28%
Heart Failure
14%
Cardiovascular Risk
14%
Glucagon Like Peptide
14%
Glucagon-Like Peptide-1 Agonist
14%
Renal Protection
14%
Apoplexy
14%
Empagliflozin
14%
Liraglutide
14%
Cardiovascular Agent
14%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
57%
Sodium Glucose Cotransporter 2 Inhibitor
28%
Death
28%
Cardiovascular Risk
14%
Heart Failure
14%
Empagliflozin
14%
Glucagon Like Peptide 1 Receptor Agonist
14%
Cardiovascular Agent
14%
Liraglutide
14%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
14%
Semaglutide
14%
Glucagon Like Peptide
14%
Neuroscience
Diabetes
100%
Sodium Glucose Cotransporter 2
28%
Agonist
14%
Glucagon-Like Peptide-1
14%
Glucagon Like Peptide
14%
Stroke
14%
Liraglutide
14%
Semaglutide
14%
Psychology
Diabetes
71%
Glucose
28%
Treatment
28%
Cotransporter
28%
Research
14%